Related Experiment Video
Updated: May 4, 2026

Semi-automated Optical Heartbeat Analysis of Small Hearts
Published on: September 16, 2009
OPTN/SRTR 2012 Annual Data Report: heart
M Colvin-Adams1, J M Smithy, B M Heubner
1Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, MN; Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN.
Insights
Heart transplant numbers are rising, but waiting list rates have declined. Despite longer waits and more pre-transplant life support, wait-list mortality hasn't increased, and pediatric graft survival improves.
Area of Science:
- Cardiology
- Transplantation Medicine
- Public Health
Background:
- The number of heart transplants is increasing, with a 25% rise in adult candidates on waiting lists between 2004 and 2012.
- The heart transplant rate per wait-list year has declined since peaking in 2007.
- There's an increasing proportion of patients requiring life support before heart transplantation.
Purpose of the Study:
- To analyze trends in heart transplantation, including waiting list dynamics, patient acuity, and outcomes.
- To examine pediatric heart transplant trends and graft survival rates.
- To assess the cost-effectiveness of heart transplantation compared to ventricular assist devices.
Main Methods:
- Analysis of national heart transplant waiting list data.
- Review of transplant procedure statistics and graft survival rates.
- Comparison of heart transplant costs and effectiveness against ventricular assist devices.
Main Results:
- Adult waiting list candidates increased by 25% (2004-2012), but the transplant rate per 100 wait-list years decreased from 149 (2007) to 93 (2012).
- The percentage of patients on life support pre-transplant rose from 48.6% to 62.7% (2007-2012), with less distinct medical urgency categories.
- Pediatric transplants increased (1998-2012), and 5-year graft survival for 2007 transplants was 78.5%.
- Heart transplant is more expensive than ventricular assist devices but more effective and likely cost-effective for end-stage heart failure.
Conclusions:
- Despite increased waiting times and pre-transplant acuity, wait-list mortality has not risen, and pediatric graft survival is improving.
- Heart transplantation remains a more effective and likely cost-effective treatment for end-stage heart failure compared to ventricular assist devices.
- Trends indicate a growing need for heart transplants, with evolving patient profiles and improving outcomes.
Abstract:
The number of heart transplants performed annually continues to increase gradually, and the number of adult candidates on the waiting list increased by 25% from 2004 to 2012. The heart transplant rate among active adult candidates peaked at 149 per 100 wait-list years in 2007 and has been declining since; in 2012, the rate was 93 heart transplants per 100 active wait-list years. Increased waiting times do not appear to be correlated with an overall increase in wait-list mortality. Since 2007, the proportion of patients on life support before transplant increased from 48.6% to 62.7% in 2012. Medical urgency categories have become less distinct, with most patients listed in higher urgency categories. Approximately 500 pediatric candidates are added to the waiting list each year; the number of transplants performed each year increased from 274 in 1998 to 372 in 2012. Graft survival in pediatric recipients continues to improve; 5-year graft survival for transplants performed in 2007 was 78.5%. Medicare paid for some or all of the care for nearly 40% of heart transplant recipients in 2010. Heart transplant appears to be more expensive than ventricular assist devices for managing end-stage heart failure, but is more effective and likely more cost-effective.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Acute Coronary Syndrome III: Diagnostic Studies
Heart Failure II: Pathophysiology
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease IV: Nursing Management

